Medical Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before starting any prescription medication.
If you've been researching weight loss medications online, you've probably encountered two names more than any others: semaglutide and Mounjaro. Four brand names. Two active ingredients. And very little clear guidance on how they actually differ or which one is more likely to work for your body.
This guide covers the clinical facts, the key differences, and how to think about which one might be right for you.
What Is Semaglutide and How Does It Work?
Semaglutide is a GLP-1 receptor agonist that mimics a hormone your body naturally produces to regulate blood sugar and appetite. By activating GLP-1 receptors in the brain and gut, semaglutide signals fullness more quickly, slows gastric emptying, and reduces the drive to eat.
Ozempic® is semaglutide at lower doses, FDA-approved to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Wegovy® is semaglutide at a higher dose (2.4 mg), FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Both are once-weekly subcutaneous injections.
Semaglutide has the longest track record of any GLP-1 medication currently in wide use.
What Is Tirzepatide (Mounjaro) and How Is It Different?
Tirzepatide targets two hormonal pathways instead of one. It is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. By activating both receptors simultaneously, it influences appetite regulation, insulin secretion, and metabolic function through two complementary pathways — which is what makes it pharmacologically distinct from semaglutide.
Mounjaro® is tirzepatide at doses FDA-approved for type 2 diabetes management. Zepbound® is the same active ingredient at doses FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Both are administered as once-weekly subcutaneous injections.
Weight Loss Results: What Do the Clinical Trials Show?
Both medications produce meaningful weight loss. Tirzepatide tends to produce higher average results.
In the STEP-1 trial, participants taking semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks, compared to 2.4% with placebo. Over 86% of participants lost at least 5% of their body weight. (Source: NEJM, 2021)
In the SURMOUNT-1 trial, participants taking tirzepatide lost an average of 16% to 22.5% of body weight at 72 weeks depending on dose. (Source: Eli Lilly / NEJM, 2022)
In the 2025 SURMOUNT-5 trial — the first head-to-head comparison, published in the New England Journal of Medicine — tirzepatide produced an average weight loss of 20.2% compared to 13.7% with semaglutide over 72 weeks. These are trial averages under controlled conditions. Real-world results vary based on adherence, individual biology, and health history. Neither result is a guarantee.
Side Effects: How Do They Compare?
Both medications share a similar side effect profile. The most common side effects for both include nausea, diarrhea, vomiting, constipation, and abdominal discomfort — most pronounced during dose escalation and typically improving over time.
Tirzepatide has additionally noted hair loss and injection site reactions. In SURMOUNT-5, GI adverse events causing discontinuation were slightly more common with semaglutide (5.6%) than tirzepatide (2.7%). Both carry a Boxed Warning regarding potential thyroid C-cell tumor risk observed in animal studies. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
Who Is a Better Candidate for Each?
Your provider should help you decide based on your specific health history. Factors include your starting weight and goal, history with GI side effects, whether you have type 2 diabetes, your blood sugar and metabolic markers, and how your body has responded to prior medications.
Tirzepatide's dual mechanism may be particularly relevant for patients with insulin resistance, metabolic syndrome, or a history of blood sugar challenges. Semaglutide's longer track record gives providers more clinical context for specific patient profiles.
Neither is universally better. The right medication is the one matched to your biology.
Compounded vs. Brand-Name: What You Should Know
Brand-name GLP-1 medications are FDA-approved at specific doses and indications, manufactured under FDA oversight. Compounded versions use the same active ingredients and are prepared by licensed, state-regulated compounding pharmacies. Compounded medications are not FDA-approved and have not undergone FDA review for safety, efficacy, or quality.
Compounded medications may be prescribed when an FDA-approved option is not medically appropriate, as determined by a licensed provider.
KINSYN offers both compounded semaglutide (kinsyn.com/weight-management/product/compounded-semaglutide) and compounded tirzepatide (kinsyn.com/weight-management/product/tirzepatide) as part of its weight management program (kinsyn.com/weight-management). The appropriate medication path is determined by a licensed provider who reviews your complete medical history through KINSYN's medical aggregator before making any recommendation.
How KINSYN Takes the Guesswork Out of the Decision
Choosing between semaglutide and tirzepatide shouldn’t come down to what you read online. It should come down to what a licensed provider sees when they look at your actual health data.
That’s what KINSYN was built to do.
KINSYN is a women’s health platform designed around the belief that better data leads to better care. Before your provider recommends anything, KINSYN’s medical aggregator pulls in up to 94.8% of your digitized medical records from participating facilities — your labs, imaging, hormones, wearables, and lifestyle data — to build a complete health profile. That means your provider isn’t guessing based on a questionnaire. They’re looking at you.
From there, your licensed KINSYN provider recommends the medication and dose most appropriate for your biology, your health history, and your goals. As your body responds, they adjust your plan in real time — with full visibility into what’s actually changing, not just how you self-reported at intake.
KINSYN’s Membership (a $99 value) comes free with any RX purchase. That means 24/7 unlimited provider messaging, wearable integration, discounted biomarker lab testing, and AI-powered personalized recommendations — all included, no extra fee.
The decision between semaglutide and tirzepatide is complex. KINSYN is here to help you make it with confidence, backed by your actual health picture.
See if you’re eligible: kinsyn.com/quiz/weight-management
The Bottom Line
Both semaglutide and tirzepatide are effective, evidence-backed GLP-1 medications for weight loss. Tirzepatide’s dual mechanism generally produces higher average weight loss in clinical trials. Semaglutide has a longer track record and works well for many patients.
The medication that’s right for you isn’t the one with the best average result. It’s the one that fits your health profile, your biology, and your goals — and a provider who actually knows your medical history is the only one who can tell you which that is.
CTA: Start your eligibility assessment at KINSYN → kinsyn.com/quiz/weight-management
Frequently Asked Questions
Is Mounjaro stronger than semaglutide?
In clinical trials, tirzepatide (the active ingredient in Mounjaro and Zepbound) has shown higher average weight loss than semaglutide. In the 2025 SURMOUNT-5 head-to-head trial, tirzepatide produced an average weight loss of 20.2% compared to 13.7% with semaglutide over 72 weeks. However, individual results vary significantly based on health history, dose, and adherence.
Can I switch from semaglutide to tirzepatide?
In many cases, yes. Switching between GLP-1 medications is something a licensed provider can help navigate based on your health history, current dose, and response to treatment. KINSYN's providers review your full medical history before making any adjustment recommendations.
What is the difference between Mounjaro and Zepbound?
Both contain tirzepatide. Mounjaro® is FDA-approved for improving blood sugar control in adults with type 2 diabetes. Zepbound® is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
Does KINSYN offer compounded tirzepatide?
Yes. KINSYN offers compounded tirzepatide as part of its weight management program. Compounded medications may be prescribed when an FDA-approved option is not medically appropriate, as determined by a licensed provider. A KINSYN provider reviews your complete health profile before any prescription is issued.
Which GLP-1 has fewer side effects?
Both share a similar side effect profile, primarily GI-related symptoms during dose escalation. In SURMOUNT-5, discontinuation due to GI side effects was slightly more common with semaglutide than tirzepatide. Individual tolerance varies and your provider can help you anticipate and manage side effects based on your specific health history.
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. KINSYN is not affiliated with or endorsed by Novo Nordisk A/S or Eli Lilly and Company.